

UNIVERSITI PUTRA MALAYSIA

SYNTHESIS AND *in vitro* VISUALIZATION OF FLUORESCEIN ISOTHIOCYANATE-LABELED CHITOSAN NANOPARTICLES (FITC-CNP) IN HUMAN KIDNEY CANCER CELLS

ANDRINA TAY CHU HUEY

FBSB 2015 139

SYNTHESIS AND *in vitro* VISUALIZATION OF FLUORESCEIN ISOTHIOCYANATE-LABELED CHITOSAN NANOPARTICLES (FITC-CNP) IN HUMAN KIDNEY CANCER CELLS



By

ANDRINA TAY CHU HUEY



Thesis submitted to the Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Cell and Molecular Biology

June 2015

Abstract of thesis presented to the Department of Cell and Molecular Biology in fulfillment of the requirement for the degree of Bachelor of Science (Hons.)

SYNTHESIS AND *in vitro* VISUALIZATION OF FLUORESCEIN ISOTHIOCYANATE-LABELED CHITOSAN NANOPARTICLES (FITC-CNP) IN HUMAN KIDNEY CANCER CELLS

By

ANDRINA TAY CHU HUEY

June 2015

Chair: Dr. Mas Jaffri Masarudin, PhD Faculty: Faculty of Biotechnology and Biomolecular Sciences

The use of fluorescently-labeled nanoparticles has garnered attention in the medical field, due to the ability to track its uptake during cell transfection. In this study, the synthesis and *in vitro* visualization of fluorescein isothiocyanate (FITC)-labeled chitosan nanoparticles (CNPs) inside human kidney cancer cells (786-O cell line) were described. CNPs were prepared using a modified ionic gelation method to yield spherical nanoparticles, and fluorescent labeling of CNP was performed using Nhydroxy-succinimidyl (NHS)-FITC. Particle size distribution and polydispersity index of nanoparticles were analyzed using dynamic light scattering. Surface morphology was analyzed using FE-SEM. For transfection, 786-O human kidney cancer cells were established and subsequently treated with both CNP and FITC-CNP, visualized at three different time points using fluorescence microscopy. It was found that 600 µl of 0.5 mg/ml chitosan with 200 µl of 0.7 mg/ml TPP gave the optimum particle size and PDI value at 71.7+0.4 nm and 0.14+0.01, respectively. FE-SEM data obtained was consistent with DLS results at optimum parameters. Visualization of cell treatment showed that at 30 mins, all FITC-CNPs were seen as small green dots with weak fluorescence residing outside of the cells at close proximity to the cell membrane. Most



of the nanoparticles internalized into the cells at 6h were seen to be in the cytoplasm or surrounding the nucleus. As time progresses to 24h, stronger fluorescence was observed with all FITC-CNPs accumulating inside cells with smearing observed, probably due to FITC detachment from CNPs. These results implied that the synthesized FITC-labeled CNPs have the potential for use as carrier system for enhanced drug delivery into cells.

Keywords: FITC-labeled CNPs, 786-O cells, chitosan nanoparticles, drug delivery system, nanobiotechnology



Abstrak thesis yang dikemukan kepada Jabatan Biologi Sel dan Molekul Sebagai syarat memenuhi keperluan untuk ijazah Sarjana Muda Sains (Kepujian)

SYNTHESIS AND *in vitro* VISUALIZATION OF FLUORESCEIN ISOTHIOCYANATE-LABELED CHITOSAN NANOPARTICLES (FITC-CNP) IN HUMAN KIDNEY CANCER CELLS

Oleh

ANDRINA TAY CHU HUEY

Jun 2015

Pengerusi: Dr. Mas Jaffri Masarudin, PhD Fakulti: Fakulti Bioteknologi dan Sains Biomolekul

Penggunaan partikel nano berpendafluor telah menarik perhatian para penyelidik terutamanya dalam bidang perubatan atas sebab kebolehannya untuk menjejaki pengambilannya ketika transfeksi sel. Dalam kajian ini, sintesis dan visualisasi in vitro bagi partikel nano kitosan (CNP) dilabel FITC (FITC-CNP) dalam sel kanser buah pinggang manusia (Titisan sel 786-O). Sintesis CNP disediakan dengan menggunakan kaedah penggelan ion yang diubah suai untuk menghasilkan partikel nano berbentuk sfera manakala pelabelan pendafluor kepada CNP dilakukan dengan menggunakan NHS-FITC. PSD dan PDI daripada partikel nano dianalisis menggunakan DLS manakala morfologi permukaan dianalisis menggunakan FE-SEM. Bagi transfeksi sel, titisan sel 786-O tetap dilaksanakan dan kemudiannya dirawat dengan CNP dan FITC-CNP, dan divisualisasi dalam tiga masa yang berbeza dengan menggunakan mikroskop pendafluor. Hasil kajian mendapati bahawa 600 μ l 0.5 mg/ml chitosan dengan 200 μ l of 0.7 mg/ml TPP memberikan saiz partikel yang optimum dan nilai PDI masing-masing pada 71.65 nm and 0.14. Data FE-SEM yang diperoleh adalah konsisten dengan keputusan DLS pada parameter optimum. Visualisasi untuk rawatan sel menunjukkan bahawa pada 30 min, semua FITC-CNP dilihat sebagai titik kecil hijau dengan



kependafluoran lemah yang berada di luar sel-sel tetapi berdekatan dengan membran sel. Kebanyakan partikel nano telah masuk ke dalam sel pada 6 j rawatan dan menetap sama ada dalam sitoplasma atau sekitar nukleus manakala setelah 24 j rawatan, kependafluoran yang lebih kuat diperhatikan dengan semua FITC-CNP yang terkumpul di dalam sel-sel dan calitan diperhatikan, mungkin disebabkan oleh penanggalan FITC daripada CNP. Hasil kajian yang didapati mengimplikasikan bahawa FITC-CNP yang efisien ke dalam sel-sel.

Kata Kunci: FITC-CNP, titisan sel 786-O, partikel nano kitosan, sistem pembawa ubatan



Approval

This thesis was submitted to the Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences and has been accepted as fulfillment of the requirement for the degree of Cell and Molecular Biology. The member of the Supervisory Committee was as follows:

Dr. Mas Jaffri Masarudin, PhD Supervisor Faculty of Biotechnology and Biomolecular Sciences Universiti Putra Malaysia

> (Dr. Janna Ong Abdullah, PhD) Head of Department Cell and Molecular Biology Faculty of Biotechnology and Biomolecular Sciences Universiti Putra Malaysia Date:

Declaration by undergraduate student

I hereby confirm that:

- this thesis is my original work
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by the Department of Cell and Molecular Biology.
- written permission must be obtained from supervisor before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials
- there is no plagiarism or data falsification/fabrication in the thesis. The thesis has undergone plagiarism detection software (TURNITIN)

| Signature: | Date: |
|--|---|
| Name and Matric No.: | |
| | |
| Declaration by Supervisor | |
| This is to confirm that: | |
| • the research conducted and the writi | ng of this thesis was under supervision |

Signature: ______ Name of Chairman of Supervisory Committee: ______

LIST OF CONTENTS

| ABSTRACT | | ii |
|--------------|--|------|
| ABSTRAK | | iv |
| APPROVAL | | vi |
| DECLARATIO | N | vii |
| ACKNOWLEI | GEMENTS | viii |
| LIST OF CON | TENTS | ix |
| LIST OF TABI | LES | xi |
| LIST OF FIGU | RES | xii |
| LIST OF ABBI | REVIATIONS & SYMBOLS | xiv |
| | | |
| CHAPTER | | |
| 1 I | NTRODUCTION | |
| 1 | .1 Research background and outline | 1 |
| 1 | .2 Objectives | 2 |
| | | |
| 2 I | ITERATURE REVIEW | |
| 2 | .1 Nanoparticles as a drug delivery system | 3 |
| 2 | .2 Nanoparticles for medical research | 5 |
| 2 | .3 Chitosan nanoparticles | 7 |
| | 2.3.1 Synthesis routes of chitosan nanoparticles | 8 |
| 2 | .4 Characterization of nanoparticles | |
| | 2.4.1 Dynamic Light Scattering (DLS) | 10 |
| 2 | 5 Visualization and localization of nanoparticles | 11 |
| | 2.5.1 Fluorescent tagging of nanoparticles | 13 |
| 2 | .6 The use of FITC for medical and biological science | 15 |
| | applications | |
| | | |
| 3 N | IATERIALS AND METHODS | |
| 3 | .1 Materials | 16 |
| 3 | .2 Synthesis of chitosan nanoparticles | 16 |
| 3 | .3 Analysis of chitosan nanoparticle size distribution using | 17 |
| | Dynamic light scattering (DLS) | |
| 3 | 4 Field emission-scanning electron microscopy (FE-SEM) | 17 |
| 3 | .5 Synthesis of FITC-CNP | |
| | 3.5.1 Preparation of FITC-chitosan (FITC-CS) | 18 |
| | 3.5.2 Synthesis of FITC-CNP | 18 |
| 3 | .6 Propagation of cells | 18 |

| | 3.7 | Cell treatment and visualization | |
|------------|-------------------|--|----|
| | | 3.7.1 Seeding of cells | 19 |
| | | 3.7.2 Treatment of cells and visualization using | 20 |
| | | fluorescence microscopy techniques | |
| 4 | RES | ULTS AND DISCUSSIONS | |
| | 4.1 | Particle size distribution | |
| | | 4.1.1 Formation of CNPs | 21 |
| | | 4.1.2 Formation of FITC-CNP | 25 |
| | 4.2 | Polydispersity index (PDI) as a measurement for | 28 |
| | | stability of nanoparticles formation | |
| | 4.3 | Morphological analysis of CNP using electron | 30 |
| | | microscopy analysis | |
| | 4.4 | Cell culture and visualization | 31 |
| | | 4.4.1 Visualization of FITC-CNP treated cells at | 33 |
| | | 30 mins, 6 h and 24 h incubation | |
| | | period | |
| | | | |
| 5 | CON | ICLUSIONS AND RECOMMENDATIONS | |
| | 5 <mark>.1</mark> | Conclusions | 36 |
| | 5 <mark>.2</mark> | Future recommendations | 37 |
| | | | |
| REFERE | NCES | | 38 |
| APPENDICES | | | 45 |
| | | | |
| | | | |
| | | | |

ACKNOWLEDGEMENTS

First and foremost, praise be to Almighty God in heaven for His blessings and guidance upon the completion of this thesis. It is only by His grace that this final year project was completed successfully throughout the year. From Him this knowledge resides and through Him it is shared.

My utmost gratitude goes to my adored supervisor, Dr. Mas Jaffri Masarudin who has shown maximum supervision and guidance throughout the project as well as in the completion of this thesis. Thank you so much for all the support, advice, guidance and encouragements showered all this while. You have indeed been such a great motivation for me to never give up despite the challenges faced in carrying out this project. Thank you also for the precious knowledge shared as I have learned a whole lot of new things throughout my Bachelor's journey.

My appreciation is further extended to my labmates and two other coursemates in the Virology Lab in Institute Bioscience with whom I have shared much joy, laughter and challenges throughout the project. To Hanis bt. Faudzi and Cha Yee Kuen- Thank you for the cooperation, support and help given in the completion of this project. To my other labmates, Ummu Afiqah and Syazaira Arham, thank you very much for your patience in assisting and guiding me throughout the journey. We have learned so much from one another throughout the journey and a strong bond of friendship was established. Thank you all for your kindness, warmth and care.

I would also like to express my gratitude and appreciation to my family who has been supporting me through prayers, motivation and encouragement all this time. To my mother, Siew Lai who never gave up on me and had been my pillar of strength whenever challenges came up, and to my father, Edmund Tay whom tells me to move on and do my best no matter what happens. As to my siblings, thank you for your encouragements, love and prayers all this while.

Thank you everyone for your support and care.

LIST OF TABLES

| Table | | Page |
|-------|--|------|
| 2.1 | An overview of different types of nanoparticles used | 4 |
| | for drug delivery (Adapted from Tang, et al., 2007) | |
| 2.2 | The different routes for chitosan nanoparticles synthesis | 9 |
| 2.3 | An overview of FE-SEM and CFM | 12 |
| 4.1 | Mean particle size obtained through DLS analysis for all | 21 |
| | CNP formulations used. Data represents three independent | |
| | measurements, with each sample analysis performed in | |
| | triplicates. The <u>+</u> symbol represents Standard Error of Mean | |
| | (SEM) with $n=3$. | |
| 4.2 | Comparison between the mean particle size and PDI value | 26 |
| | for CNP-F3 only and FITC-CNP. Data represents | |
| | mean \pm SEM, $n=3$. | |
| 4.3 | Mean PDI values for all formulations of CNP. Data represents | 29 |
| | mean \pm SEM, $n=3$. | |

xi

LIST OF FIGURES

| Figure | e | Page |
|--------|--|------|
| 2.1 | Chitosan structure (Adapted from Mahapatro and Singh, 2011) | 8 |
| 2.2 | Schematic diagram depicting the cross-linking reaction of | 10 |
| | chitosan with TPP to form chitosan nanoparticles | |
| | (Adapted from Yang, et al., 2009) | |
| 2.3 | An illustration of an optical configuration of an experimental | 11 |
| | setup for measurements of dynamic light scattering | |
| | (Adapted from Lim, et al., 2013) | |
| 4.1 | Mean particle size distribution of (a) CNP-F1, (b) CNP-F2 and | 22 |
| | (c) CNP-F3. Data represents three independent measurements, | |
| | with each sample analysis performed in triplicates. The "I" symbol | |
| | represents Standard Error of Mean (SEM), with $n=3$ | |
| 4.2 | DLS peak spectra of (a) 600 μ l chitosan only, and after | 24 |
| | (b) 200 μ <mark>l TPP addition for CNP-F₃. Samples were</mark> analyzed as | |
| | Independent triplicates to ensure consistency and stability of data | |
| | acquisition. Figure (a) shows that chitosan only had multiple peaks | |
| | due to chitosan polymers of different sizes while (b) appeared as | |
| | single peak only as a result of stable and uniformed nanoparticle | |
| | formation after TPP addition | |
| 4.3 | (a) Mean particle size and (b) Mean PDI value of CNP-F ₃ and | 26 |
| | FITC-CNP with a FITC concentration of 0.20 mg/ml. Data | |
| | represent the mean \pm SEM, $n = 3$. | |
| 4.4 | Particle size distribution of stable and uniform FITC-CNP | 26 |
| | (blue arrow) and CNP-F3 at optimum size (red arrow) | |
| 4.5 | Particle size distribution of unstable FITC-CNP (mixture of CNP | 28 |
| | and CNP-FITC samples), (b) Particle size distribution of stable and | |
| | uniform FITC-CNP. These figures depict the transition period of | |
| | CNP to form FITC-CNP thus producing two peaks in (a) whereas | |
| | in (b), single peak indicated that all CNP have been successfully | |
| | tagged to FITC thereby producing stable and uniformed FITC-CNPs. | |

| 4.6 | Mean PDI distribution for all CNP formulations, CNP-F1, CNP-F2 | 30 |
|-----|--|----|
| | and CNP-F3 at TPP volumes of 0 μ l to 300 μ l. Data represents | |
| | mean + SEM, n = 3. | |
| 4.7 | FE-SEM results of CNP-F ₃ at a volume of 600 μ l chitosan | 31 |
| | solution and 200 μ l TPP solution. The CNP size ranges from | |
| | 60 nm to 100 nm. The black swirl at the bottom of the image | |
| | denotes sample imperfections during preparation, and is not | |
| | indicative of the nanoparticle samples. | |
| 4.8 | Brightfield(a) and fluorescence (b) microscopic images of controls | 33 |
| | and CNP-FITC at 24 hours incubation period. Cells were viewed at | |
| | 10X magnification on an Olympus fluorescent microscope. | |
| 4.9 | Brightfield (a) and fluorescence (b) microscopic images of cells | 36 |
| | treated with FITC-CNP at three different incubation periods; | |
| | 30 mins, 6 h and 24 h. Cells were viewed at | |
| | 10X magnification on an Olympus fluorescent microscope. | |

 \bigcirc

LIST OF ABBREVIATIONS AND SYMBOLS

| А | -absorbance |
|-----------------------------------|--|
| 0 | -degree |
| x- Fe ₂ O ₃ | -superparamagnetic nanoparticles |
| С | -Celcius |
| CDDP | -cis-diamminedichloroplatinum (II) |
| CFM | -confocal fluorescence microscopy |
| CO ₂ | -carbon dioxide |
| CS | -chitosan |
| CNP/s | -chitosan nanoparticle/s |
| DLS | -dynamic light scattering |
| DMSO | -dimethyl sulfoxide |
| DNA | -deoxyribonucleic acid |
| DOX | -doxorubicin |
| EPR | -enhanced permeability effect |
| FE-SEM | -field emission-scanning electron microscopy |
| FITC | -fluorescein isothiocyanate |
| g | -grams |
| h | -hour(s) |
| HCl | -hydrochloric acid |
| HGC | -hydrophobically modified glycol chitosan |

| hMSCs | -human mesenchymal cells |
|-------|---|
| HFT-T | -heparin-folic acid-paclitaxel loaded with paclitaxel |
| 1 | -litre |
| m | -metre |
| mg | -milligram |
| min | -minute(s) |
| ml | -mililitre |
| MNPs | -magnetic nanoparticles |
| MRI | -magnetic resonance imaging |
| MSNs | -mesoporous silica nanoparticles |
| NaOH | -sodium hydroxide |
| NaTC | -sodium taurocholate |
| nm | -nanometer |
| NPs | -nanoparticles |
| PBS | -phosphate buffer saline |
| PDI | -polydispersity index |
| PSD | -particle size distribution |
| rMSCs | -rat mesenchymal stem cells |
| rpm | -revolutions per minute |
| S | -second(s) |
| SiNPs | -silica nanoparticles |

- SiO₂ -silicon dioxide
- TPP -(sodium) tripolyphosphate
- UV -ultraviolet
- % -percentage
- μ -micro



CHAPTER 1

INTRODUCTION

1.0 Research background and outline

Nanoparticles are an important aspect in the field of nanobiotechnology, a cross-over between nanotechnology- and biology-related fields to create materials for studying biological systems (Gazit, 2007). It can be defined as particles within the size range of 1 and 100 nm and shows unique properties that differ from those observed in bulk samples of the same material (Auffan *et al.*, 2009). In the recent years, chitosan nanoparticles have received considerable attention due to its low toxicity as well as its biodegradable and biocompatible properties, which forms an ideal hydrophilic carrier system (Hirano, 1996). Chitosan is usually derived from a naturally occurring substance known as chitin usually found in the exoskeletons of insects, crustaceans and some cell walls of certain fungi species (Jia *et al.*, 2009). Methods that can be used to prepare chitosan nanoparticles include ionic cross-linking, polymerization, precipitation and self-assembly (Wang *et al.*, 2011). The co-administration of chitosan and its derivatives have led to an improved bioavailability of various pre-orally given drugs such as doxorubicin hydrochloride and insulin (Takeuchi *et al.*, 2003).

The use of chitosan nanoparticles as efficient drug and gene delivery systems requires that its uptake effectiveness into its target site to be assessed to confirm successful cellular internalization. In addition, its accumulation efficiency inside cells at different time points is also another important aspect that needs to be studied to ensure efficient drug release or retention inside cells. This can be ascertained through the *in vitro* labeling of chitosan nanoparticles with suitable markers such as FITC to visualize and track cellular localization (Jia *et al.*, 2009). Also, the efficiency of accumulation inside cells after cellular uptake at different time points has to be taken into account in order to ensure efficient drug release or retention as desired. FITC is a type of fluorophore derived from fluorescein which that emits green fluorescence and is usually covalently attached onto polysaccharide molecules such as chitosan, alginate, dextran and starch (Chin *et al.*, 2014). In previous years,

 \bigcirc

fluorophores were physically entrapped for incorporation into nanoparticles due to its simplicity but this has caused major drawbacks such as fluorophore leaching leading to cell toxicity, contamination of samples and incorrect signal measurements. Therefore, the recent approach of covalent attachment was proven to reduce fluorophore leaching, improved photostability, more stable fluorescent signals and enhanced lifetime FITC as compared to physical entrapment of fluorophores (Schulz *et al.*, 2009).

In this study, chitosan nanoparticles were synthesized using ionic crosslinking route and then labeled with the FITC dye for *in vitro* visualization and localization into 786-O human kidney cancer cell line using fluorescence microscopy techniques. The chitosan nanoparticles were characterized using dynamic light scattering (DLS) for particle size distribution and polydispersity index evaluation. Finally, the nanoparticles were labeled with FITC, followed by treatment of human kidney cancer cells *in vitro* and visualization using fluorescence microscopy.

1.2 OBJECTIVES

There are basically three objectives of this project, as mentioned below:

1. To synthesize chitosan nanoparticles using ionic gelation method

2. To label the chitosan nanoparticles with FITC dye for visualization and localization inside human kidney cancer cells

3. To observe the uptake of FITC-labeled chitosan nanoparticles into human cancer kidney cells.

REFERENCES

- Allouche, J. (2013). Synthesis of Organic and Bioorganic Nanoparticles: An Overview of the Preparation Methods. <u>In</u>: *Nanomaterials: A Danger or a Promise?*, eds.
 R. Brayner, F. Fiévet, T. Coradin, Vol 1, pp 27-53. Verlag London. Springer. ISBN 978-1-4471-4213-3.
- Auffan, M., Rose, J., Bottero, J-Y., Lowry, G.V., Jolivet, J-P and Wiesner, M.R. (2009). Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. *Nature Nanotechnology* 4: 634-641.
- Brar, S.K and Verma, M. (2011). Measurement of nanoparticles by light-scattering techniques. *Trends in Analytical Chemistry* 30(1): 4-17.
- Cadogan, E.I., Lee, C-H., Popuri, S.R. and Lin, H-Y. (2014). Efficiencies of chitosan nanoparticles and crab shell particles in europium uptake from aqueous solutions through biosorption: Synthesis and characterization. *International Biodeterioration & Biodegradation*. pp 1-9.

http://dx.doi.org/10.1016/j.ibiod.2014.06.003

- Calvo, P., Remunan-Lopez, R., Vila-Jato, C.J.L. and Alonso, M.J. (1997). Chitosan and chi-tosan/ethylene oxide–propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. *Pharmaceutical Research Journal* 14:1431–1436.
- Chekina, N., Horák, D., Jendelová, P., Trchová, M., Beneš, M.J., Hrub, M., Herynek,
 V., Turnovcová, K. and Syková, E. (2011). Fluorescent magnetic nanoparticles
 for biomedical applications. *Journal of Materials Chemistry* 21: 7630-7637.
- Chen, F., Zhang, Z-R., Yuan, F., Qin, X., Wang, M. and Huang, Y. (2008). *In vitro* and *in vivo* study of N-trimethyl chitosan nanoparticles for oral protein delivery. *International Journal of Pharmaceutics* 349: 226-233.

- Chin, S.F., Azman, A., Pang, S.C. and Ng, S.M. (2014). Fluorescein-Labeled Starch Maleate Nanoparticles as Sensitive Fluorescent Sensing Probes for Metal Ions. *Journal of Nanomaterials, pages* 1-8.
- Chung, T.H., Wu, S.H., Yao, M., Lu, C.W., Lin, Y.S., Hung, Y., Mou, C.Y., Chen, Y.C. and Huang, D.M. (2007). The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. *Biomaterials* 28: 2959–2966.
- Delie, F. (1998). Evaluation of nano- and microparticle uptake by the gastrointestinal tract. *Advanced Drug Delivery Rev*iew 34: 221–223.
- Demel, U., Fo⁻Ides-Papp, Z. and Tilz, G.P. (2003). Laser scanning confocal fluorescence microscopy: An overview. *International Immunopharmacology* 3: 1717.
- Dong, Y.C., Ng, W.K., Shen, S.C., Kim, S. and Tan, R.B.H. (2013). Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. *Carbohydrate Polymers* 94: 940-945.
- El-Shabouri M. (2002). Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. *International Journal of Pharmaceutics* 249(1-2): 101–108.
- Fan, W., Yan, W., Xu, Z. and Ni, H. (2012). Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. *Biointerface* 90: 21-27.
- Feng, C., Wang, Z., Jiang, C., Kong, M., Zhou, X., Li, Y., Cheng, X. and Chen, X. (2013). Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: *In vitro* and in vivo evaluation. *International Journal of Pharmaceutics* 457: 158–167.

- Gan, Q. and Wang, T. (2007). Chitosan nanoparticle as protein delivery carrier— Systematic examination of fabrication conditions for efficient loading and release. *Colloids and Surfaces B: Biointerfaces* 59: 24–34.
- Gan, Q., Wang, T., Cochrane, C. and McCarron, P. (2005). Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. *Colloids and Surfaces B: Biointerfaces* 44: 65–73.
- Gazit, E. (2007). Introduction: Nanobiotechnology and Bionanotechnology. <u>In</u>: Plenty of room for biology at the bottom: An Introduction to bionanotechnology. Vol. pp 1-15. Imperial College Press, ISBN 978-1-86094-677-6.
- Ge, Y., Zhang, Y., He, S., Nie, F., Teng, G. and Gu, N. (2009). Fluorescence Modified Chitosan-Coated Magnetic Nanoparticles for High-Efficient Cellular Imaging. *Nanoscale Research Letters* 4: 287-295.
- Gelperina, S., Kisich, K., Iseman, M.D. and Helfets, L. (2005). The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine 172: 1487-1490.
- Havrdova, M., Polakova, K., Skopalik, J., Vujtek, M., Mokdad, a., Homolkova, M., Tucek, J., Nebesarova, J. and Zboril, R. (2014). Field emission scanning electron microscopy (FE-SEM) as an approach for nanoparticle detection inside cells. *Micron* 67: 149-154.

Hirano, S. (1996). Chitin biotechnology applications. *Biotechnology Annual Review* 2: 237–258.

- Hejazi, R. and Amiji, M. (2003). Chitosan-based gastrointestinal delivery systems. *Journal of Controlled Release* 89: 151–165.
- Huang, M., Ma, Z., Khor, E. and Lim, L.Y. (2002). Uptake of FITC-Chitosan Nanoparticles by A549 Cells. *Pharmaceutical Research* 19(10): 1488-1493.

- Jia, X., Chen, X., Xu, Y., Han, X. and Xu, Z. (2009). Tracing transport of chitosan nanoparticles and molecules in Caco-2 cells by fluorescent labelling. *Carbohydrate Polymers* 78: 323–329.
- Jing, J., Chen, X.G., Peng, W.B. and Liu, C.S. (2008). Uptake of oleoyl-chitosan nanoparticles by A549 cells. *Nanomedicine: Nanotechnology, Biology and Medicine* 4: 208-214.
- Kamen, B.A. and Capdevilla, A. (1986). Receptor-mediated folate accumulation is regulated by the cellular folate content. *Cell Biology* 83: 5983-5987.
- Kim, J.H., Kim, Y.S., Park, K., Nam, H.Y., Park, J.H., Choi, K., Jeong, S.Y., Park, R.W., Kim, I.S., Kim, K. and Kwon, I.C. (2008). Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. *Journal of Control Release* 127: 41–49.
- Lakshmanan, V.K., Snima, K.S., Bumgardner, J.D., Nair, S.V. and Jayakumar, R. (2011). Chitosan-Based Nanoparticles in Cancer Therapy. Advanced Polymer Science 243: 57-58.
- Lamprecht, A. and Schmidt, C. (2009). Nanocarriers in drug delivery –Design, manufacture and physicochemical properties, Part 1: general aspects of nanotherapeutics. <u>In</u>: *Nanotherapeutics: Drug delivery concepts on nanoscience*, ed. A. Lamprecht, Vol 1. pp 3-30. Singapore. Pan Stanford. ISBN 13 978-981-4241-02-1.
- Li, F., Li, J., Wen, X., Zhou, S., Tong, X., Su, P., Li, H. and Shi, D. (2009). Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An *in vitro* study. *Materials Science and Engineering C* 29: 2392–2397.
- Lim, J.K., Yeap, S.P., Che, H.X. and Low, S.C. (2013). Characterization of magnetic nanoparticle by dynamic light scattering. *Nanoscale Research Letters* 8(381): 1-14.

- Mahapatro, A. and Singh, D.K. (2011). Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. *Journal of Nanobiotechnology* 9:55 http://www.jnanobiotechnology.com/content/9/1/55 [accessed 10 April 2015]
- MacLaughlin, F.C., Mumper, R.J., Wang, J., Tagliaferri, J.M., Gill, I., Hinchcliffe, M. and Rolland, A.P. (1998). Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. *Journal of Controlled Release* 56: 259–272.

McNeil, S.E. (2005). Nanotechnology for the biologist. *Journal of Leukocyte Biology* 78: 1–10.

- Moorthi, C., Manavalan, R. and Kathiresan, K. (2011). Nanotherapeutics to Overcome Conventional Cancer Chemotherapy. *Journal of Pharmaceutical Science* 14(1): 67-77.
- Nair, B.J., Sivakumar, T.T., Joseph, A.P., Varun, B.R. and Mony, V. (2012). Special sections: Dentistry Reviews-Confocal Microscopy. *Health science* 3: 2.
- Park, J.H., Kwon, S., Lee, M., Chung, H., Kim, J.H., Kim, Y.S., Park, R.W., Kim, I.S., Seo, S.B., Kwon, I.C. and Jeong, S.Y. (2006). Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: *In vivo* biodistribution and anti-tumor activity. *Biomaterials* 27: 119-126.
- Rampino, A., Borgogna, M., Blasi, P., Bellich, B. and Cesaro, A. (2013). Chitosan nanoparticles: Preparation, size evolution and stability. *International Journal of Pharmaceutics* (455): 219-228.
- Richardson, S.C., Kolbe, H.V. and Duncan, R. (1999). Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. *International Journal of Pharmaceutics* 178: 231-243.

- Sailaja, K. and Amareshwar, P. (2011). Preparation of chitosan coated nanoparticles by emulsion polymerization technique. *Asian Journal of Pharmaceutical and Clinical Research* 4: 73-74.
- Saravanakumar, G., Park, J.H., Kim, K. and Kwon, I.C. (2010). Targeted delivery of low molecular drugs using chitosan and its derivatives. *Advanced Drug Delivery Review* 62(1): 28.
- Schulz, A., Hornig, S., Liebert, T., Birckner, E., Heinze, T and Mohr, G.J. (2009). Evaluation of fluorescent polysaccharide nanoparticles for pH-sensing. Organic and Biomolecular Chemistry 7(9): 1884–1889.
- Sevda, S. and McClureb, S.J. (2004). Potential applications of chitosan in veterinary medicine. *Advanced Drug Delivery Review* 56: 1467-1480.
- Song, Z., Zvyagin, A.V., Nadort, A., Sreenivasan, V.K.A. and Deyev, S.M. (2013). Luminescent Nanomaterials for Molecular-Specific Cellular Imaging. In: *Handbook of Nano-Optics and Nanophotonics*, ed. M. Ohtsu, Vol 1. pp 563-596. Verlag Berlin Heidelberg. Springer. ISBN 978-3-642-31065-2.
- Takeuchi, H., Matsui, Y., Yamamoto, H. and Kawashima, Y. (2003). Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. *Journal of Controlled Release*. 86(2–3): 235–242.
- Tang, M., Russell, P.J. and Khatri, A. (2009). Magnetic nanoparticles: Prospects in cancer imaging and therapy. *Discovery Medicine* 7(38): 68-74.
- Veeranarayanan, S., Poulose, A.C., Mohamed S., Aravind, A., Nagaoka, Y., Yoshida, Y., Maekawa, T. and Kumar, D.S. (2012). FITC Labeled Silica Nanoparticles as Efficient Cell Tags:Uptake and Photostability Study in Endothelial Cells. *Journal of Fluorescence* 22: 537-548.

- Vimal, S., Majeed, S.A., Taju, G., Nambi, K.S.N, Raj, N.S., Madan, N., Farook, M.A., Rajkumar, T., Gopinath, D. and Hameed, A.S.S. (2013). Chitosan tripolyphosphate (CS/TPP) nanoparticles: Preparation, characterization and application for gene delivery in shrimp. *Acta Tropica* 128: 486–493.
- Wang, J.J., Zeng, Z.W., Xiao, R.Z., Xie, T., Zhou, G.L., Zhan, X.R. and Wang, S.L. (2011). Recent advances of chitosan nanoparticles as drug carriers. *International Journal of Nanomedicine* 6: 765–774.
- Wang, X., Li, J., Wang, Y., Cho, K.J., Kim, G., Gjyrezi, A., Koenig, L., Giannakakou,
 P., Shin, H.J.C., Tighiouart, M., Nie, s., Chen, Z. and Shin, D.M. (2009). HFTT, a Targeting Nanoparticle, Enhances Specific Delivery of Paclitaxel to Folate
 Receptor-Positive Tumors, ACS Nano 3(10): 3165-3174.

Weissleder, R. (2001). A clearer vision for in vivo imaging. *Nature Biotechnology* 19: 316–317.

- Win, K.Y. and Feng, S.S. (2005). Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. *Biomaterials* 26: 2713-2722.
- Xu, C., Cai, X., Zhang, J. and Liu, L. (2014). Fast nanoparticle sizing by image dynamic light scattering. *Particuology*, pages1-4.
- Yacobi, B.G. and Holt, D.B. (1994). Scanning electron microscopy. <u>In</u>: Microanalysis of solids, eds. L.L. Kazmerski, B.G. Yacobi, D.B Holt, Vol 1. pp 25-26. United States. Spinger, ISBN 0-306-44433-X.
- Yang, C.H., Lin, Y.S., Huang, K.S., Huang, Y.C., Wang, E.C., Jhong, J.Y., and Kuo, C.Y. (2009). Microfluidic emulsification and sorting assisted preparation of monodisperse chitosan microparticles. *Lab on a chip* 9(1): 145-150.
- Yucel,C., Degim, Z. and Yilmaz, S. (2013). Nanoparticle and liposome formulations of doxycycline: Transport properties through Caco-2 cell line and effects on matrix metalloproteinase secretion, *Biomedicine & Pharmacotherapy* 67: 459-467.